Furthermore, alvocidib displays synergistic effects when administered with selective BH3 mimetic BCL-2 inhibitors (ABT-199 or venetoclax) in in vitro and in vivo models of AML [163]. Here, BCL2 is linked to acute myeloid leukemia.